Vanflyta is a cancer medicine used to treat adults who have been newly diagnosed with acute myeloid leukaemia (AML), a cancer of the white blood cells. It is only given to those patients whose cancer cells have a particular change (mutation) known as ITD in the gene for a protein called FLT3. Vanflyta is used together with cytarabine and anthracycline (other cancer medicines, also called chemotherapy) at induction (start of treatment) . After induction it is used in combination with cytarabine alone (consolidation). It is then used on its own as maintenance therapy. Vanflyta contains the active substance quizartinib.
Therapeutic Indication
### Therapeutic indication Vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by Vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.
Therapeutic Area (MeSH)
N/AATC Code
L01EX11
ATC Item
quizartinib
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Quizartinib dihydrochloride | N/A | Quizartinib |
| quizartinib dihydrochloride | N/A | Quizartinib |
EMA Name
Vanflyta
Medicine Name
Vanflyta
Aliases
N/ANo risk management plan link.
